Tussionex, Hydrocodone Polistirex, Chlorpheniramine Polistirex Newswire

Tussionex, Hydrocodone Polistirex, Chlorpheniramine Polistirex Newswire

Comprehensive Real-Time News Feed for Tussionex, Hydrocodone Polistirex, Chlorpheniramine Polistirex (generic).

Results 1 - 20 of 29 in Tussionex, Hydrocodone Polistirex, Chlorpheniramine Polistirex (generic)

  1. Neos Therapeutics Inc (NEOS) Cut to Hold at Zacks Investment ResearchRead the original story w/Photo

    Saturday May 21 | AmericanBankingNews.com

    According to Zacks, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage.

    Comment?

  2. Neos Therapeutics Inc (NEOS) Downgraded by Zacks Investment Research to "Hold"Read the original story w/Photo

    Wednesday May 18 | Daily Political

    According to Zacks, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage.

    Comment?

  3. Neos Therapeutics Inc (NEOS) Rating Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Wednesday May 18 | AmericanBankingNews.com

    According to Zacks, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage.

    Comment?

  4. Neos Therapeutics Closes $60 Million Term Debt Financing DealRead the original story

    Sunday May 15 | BioSpace

    Neos Therapeutics, Inc. , a pharmaceutical company focused on developing and commercializing innovative extended-release products for the treatment of attention-deficit/hyperactivity disorder , today announced the closing of a $60 million term loan from Deerfield Management. The Company also provided a business update and announced financial results for the first quarter ended March 31, 2016.

    Comment?

  5. Neos Therapeutics Inc (NEOS) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    Apr 24, 2016 | AmericanBankingNews.com

    The brokerage currently has a $11.00 price objective on the stock. Zacks Investment Research 's price target indicates a potential upside of 8.80% from the company's current price.

    Comment?

  6. STATE v. PHILLIPSRead the original story w/Photo

    Feb 19, 2016 | FindLaw

    E. Charles Grose, Jr., of The Grose Law Firm, of Greenwood, for Petitioner. Attorney General Alan M. Wilson and Assistant Attorney General J. Benjamin Aplin, both of Columbia, for Respondent.

    Comment?

  7. Neos Therapeutics Inc's Lock-Up Period To End on January 19thRead the original story w/Photo

    Jan 11, 2016 | AmericanBankingNews.com

    Neos Therapeutics' lock-up period will end on Tuesday, January 19th. Neos Therapeutics had issued 4,800,000 shares in its IPO on July 23rd, MarketBeat Ratings reports.

    Comment?

  8. Brokerages Set $32.50 Price Target for Neos Therapeutics IncRead the original story w/Photo

    Dec 9, 2015 | AmericanBankingNews.com

    Shares of Neos Therapeutics Inc have received an average broker rating score of 1.50 from the two brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.

    Comment?

  9. Neos Therapeutics PT Lowered to $33.00 at RBC CapitalRead the original story

    Nov 15, 2015 | AmericanBankingNews.com

    The brokerage currently has an "outperform" rating on the stock. RBC Capital's price objective points to a potential upside of 128.85% from the stock's current price.

    Comment?

  10. JMP Securities Boosts Neos Therapeutics Price Target to $33.00Read the original story

    Nov 14, 2015 | AmericanBankingNews.com

    The firm currently has a "market outperform" rating on the stock. JMP Securities' price objective suggests a potential upside of 128.85% from the company's current price.

    Comment?

  11. Neos Therapeutics Shares Up 3.7% on Analyst UpgradeRead the original story

    Nov 12, 2015 | AmericanBankingNews.com

    Shares of Neos Therapeutics shot up 3.7% on Thursday after JMP Securities raised their price target on the stock to $33.00, Marketbeat.com reports. JMP Securities currently has a market outperform rating on the stock.

    Comment?

  12. Neos Therapeutics Price Target Increased to $33.00 by Analysts at JMP SecuritiesRead the original story

    Nov 12, 2015 | AmericanBankingNews.com

    The brokerage currently has a "market outperform" rating on the stock. JMP Securities' price objective would indicate a potential upside of 131.09% from the company's current price.

    Comment?

  13. Neos Therapeutics To Present At Stifel Healthcare Conference On November 18, 2015Read the original story

    Nov 11, 2015 | BioSpace

    Neos Therapeutics, Inc. , a pharmaceutical company with a late-stage pipeline of innovative extended-release product candidates for the treatment of attention deficit hyperactivity disorder , today announced that Vipin Garg, PhD, President and CEO, will present at the Stifel 2015 Healthcare Conference on November 18, 2015 at 3:00 p.m. ET in New York. Dr. Garg will provide a corporate update and discuss the company's key milestones and events since their initial public offering.

    Comment?

  14. Neos Therapeutics Receives Complete Response Letter From The FDA For Cotempla XR-ODTRead the original story

    Nov 10, 2015 | BioSpace

    Neos Therapeutics, Inc. , a pharmaceutical company with a late-stage pipeline of innovative extended-release product candidates for the treatment of attention deficit hyperactivity disorder , today announced that the Company received a Complete Response Letter from the U.S. Food and Drug Administration regarding the Company's New Drug Application for Cotempla XR-ODTa 10mg, 20mg, and 30mg tablets. Neos Therapeutics also announced financial results for the third quarter ended September 30, 2015.

    Comment?

  15. FDA Finds Deficiencies in Neos Therapeutics' Marketing ApplicationRead the original story

    Oct 19, 2015 | BioSpace

    The FDA stated that this notification does not reflect a final decision on the information under review. In a letter dated March 24, 2015, the FDA had set November 9, 2015 as the target date for a decision on the NDA.

    Comment?

  16. Neos Therapeutics Cotempla XR-Odt Fda UpdateRead the original story

    Oct 19, 2015 | Business Wire

    The FDA stated that this notification does not reflect a final decision on the information under review. In a letter dated March 24, 2015, the FDA had set November 9, 2015 as the target date for a decision on the NDA.

    Comment?

  17. Tris Pharma launches its Tussionex genericRead the original story w/Photo

    Oct 1, 2015 | Drug Store News

    Specialty pharmaceutical company Tris Pharma on Thursday announced that it had launched its generic version of Tussionex extended-release suspension. The drug is indicated to treat cough and upper respiratory symptoms of allergies and colds, and will be available in 115- and 473-ml bottles.

    Comment?

  18. Tris Pharma, Inc. Launches Generic Tussionex As Par's Rights ExpireRead the original story

    Sep 30, 2015 | BioSpace

    TussionexA , originally approved in the early 1980's, had no generic competition until 2010 when Tris Pharma's generic product entered the market under an exclusive distribution agreement with Par Pharmaceuticals. Under the terms of the distribution agreement, Par had the exclusive right to market Tris Pharma's hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension for a five year period ending , hydrocodone polistirex and chlorpheniramine polistirex ER Suspension in 115ml and 473 ml bottles will be marketed and distributed by Tris Pharma's generic business.

    Comment?

  19. Vernalis Therapeutics Launches Long-Acting Codeine-Based Cough...Read the original story w/Photo

    Sep 7, 2015 | BioSpace

    It is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. Tuzistra XR was developed using a liquid sustained release technology, LiquiXR, which enables a 12-hour dosing period.

    Comment?

  20. Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.Read the original story w/Photo

    Sep 8, 2015 | Medical News

    Vernalis Therapeutics Inc., a subsidiary of Vernalis plc , today announced that Tuzistra XR , extended-release oral suspension, CIII is now available to adult patients and physicians in the United States. Tuzistra XR, the only codeine-based cough and cold syrup dosed every 12 hours, was approved by the U.S. Food and Drug Administration on April 30, 2015.

    Comment?